Literature DB >> 7842467

cAMP concentrations, cAMP dependent protein kinase activity, and phospholamban in non-failing and failing myocardium.

M Böhm1, B Reiger, R H Schwinger, E Erdmann.   

Abstract

OBJECTIVE: Several signal transduction defects such as a reduction of myocardial cAMP formation and an altered intracellular Ca2+ handling have been observed in the failing human myocardium. The aim of the study was to obtain data on changes beyond cAMP formation involving cAMP dependent protein kinase and its substrates.
METHODS: cAMP dependent protein kinase activity and cAMP concentrations were measured in the particulate and soluble fraction of failing human hearts (ischaemic, and dilated cardiomyopathy) and non-failing donor hearts. Phospholamban was quantified by cAMP dependent phosphorylation using 32P-ATP as substrate and on western blots using a monoclonal antibody.
RESULTS: cAMP concentrations were reduced in the particulate fraction in both ischaemic and dilated cardiomyopathy and in the soluble fraction in dilated cardiomyopathy, but there was no difference in cAMP dependent protein kinase activity. Both phospholamban levels and cAMP dependent phosphorylation of phospholamban were similar in non-failing myocardium and in both ischaemic and dilated cardiomyopathy.
CONCLUSIONS: These findings show that the reduction of cAMP formation is the predominant alteration in heart failure, but cAMP dependent protein kinase and phospholamban are evidently unchanged.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7842467     DOI: 10.1093/cvr/28.11.1713

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  24 in total

Review 1.  Transcriptional regulation by cAMP in the heart.

Authors:  F U Müller; J Neumann; W Schmitz
Journal:  Mol Cell Biochem       Date:  2000-09       Impact factor: 3.396

Review 2.  Altered intracellular Ca2+ handling in heart failure.

Authors:  Masafumi Yano; Yasuhiro Ikeda; Masunori Matsuzaki
Journal:  J Clin Invest       Date:  2005-03       Impact factor: 14.808

Review 3.  Remodeling of excitation-contraction coupling in the heart: inhibition of sarcoplasmic reticulum Ca(2+) leak as a novel therapeutic approach.

Authors:  Stefan Neef; Lars S Maier
Journal:  Curr Heart Fail Rep       Date:  2007-03

4.  Protein phosphorylation in isolated trabeculae from nonfailing and failing human hearts.

Authors:  S Bartel; B Stein; T Eschenhagen; U Mende; J Neumann; W Schmitz; E G Krause; P Karczewski; H Scholz
Journal:  Mol Cell Biochem       Date:  1996 Apr 12-26       Impact factor: 3.396

Review 5.  Adrenergic and muscarinic receptor regulation and therapeutic implications in heart failure.

Authors:  W Schmitz; P Boknik; B Linck; F U Müller
Journal:  Mol Cell Biochem       Date:  1996 Apr 12-26       Impact factor: 3.396

6.  Acceleration of contraction by beta-adrenoceptor stimulation is greater in ventricular myocytes from failing than non-failing human hearts.

Authors:  S E Harding; L A Brown; F del Monte; C H Davies; P O'Gara; G Vescovo; D G Wynne; P A Poole-Wilson
Journal:  Basic Res Cardiol       Date:  1996       Impact factor: 17.165

Review 7.  Regulation of heterotrimeric G-protein signaling by NDPK/NME proteins and caveolins: an update.

Authors:  Issam H Abu-Taha; Jordi Heijman; Yuxi Feng; Christiane Vettel; Dobromir Dobrev; Thomas Wieland
Journal:  Lab Invest       Date:  2017-10-16       Impact factor: 5.662

8.  Effects of cantharidin on force of contraction and phosphatase activity in nonfailing and failing human hearts.

Authors:  B Linck; P Boknik; J Knapp; F U Müller; J Neumann; W Schmitz; U Vahlensieck
Journal:  Br J Pharmacol       Date:  1996-10       Impact factor: 8.739

Review 9.  Calcium transport proteins in the nonfailing and failing heart: gene expression and function.

Authors:  M Wankerl; K Schwartz
Journal:  J Mol Med (Berl)       Date:  1995-10       Impact factor: 4.599

Review 10.  PDE3 inhibition in dilated cardiomyopathy.

Authors:  Matthew Movsesian; Omar Wever-Pinzon; Fabrice Vandeput
Journal:  Curr Opin Pharmacol       Date:  2011-09-28       Impact factor: 5.547

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.